Sarepta Therapeutics (NASDAQ:SRPT)
CAPS Rating:
A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.
The World's Greatest Investing Community
A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Looks like a reversal day to me. Although this company has lots of potential in the long term, I think in the short term it will drop back down to earth since it is still some time before FDA approval.